Non-invasive Early Detection of Colorectal Cancer Using Urine Metabolite Analysis in Adults Aged 50 to 70

What this Trial Is About

Colorectal cancer is a common tumor affecting both men and women, with a high number of new cases and deaths each year, especially in people over 50 years old. This research aims to find if specific substances called metabolites in urine or stool can help detect colorectal cancer or polyps early in an easy and affordable way. Early detection is important because it can reduce cancer deaths and prevent polyps from turning into cancer. Participants will provide urine and stool samples before undergoing a colonoscopy, which is a procedure used to examine the colon and detect any abnormal growths or cancer. The study groups include patients diagnosed with colorectal cancer, those with various risk levels of adenomatous polyps, and healthy individuals with no lesions found during colonoscopy. Urine and fecal occult blood tests FOBT are collected prior to the colonoscopy and diet preparation. During the study, participants will have colonoscopy results reviewed within three months. Researchers will analyze urine and stool samples using metabolomics techniques to identify possible markers for early cancer detection. The study involves patients referred after a positive FOBT test and monitors their colonoscopy findings to assess potential non-invasive diagnostic methods. Participation duration varies, with primary outcomes measured three months after colonoscopy.

Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile